Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Frank Clark

Cytosorbents Corporation

CytoSorb® therapy for Liver and Kidney

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption technology. CytoSorbents is a leader in the treatment of life-threatening conditions in the ICU and cardiac surgery using blood purification.  Its flagship product, CytoSorb®, is distributed in more than 70 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorbents has multiple active, clinical trials ongoing, including two pivotal randomized, controlled trials in the United States designed to support eventual FDA marketing approval for antithrombotic removal during cardiothoracic surgery using the DrugSorb™-ATR Antithrombotic Removal System.

Metric
Company Name	Cytosorbents Corporation
Symbol	CTSO
MSH ID	COM:CYTOSORBENTS
Market	STOCKS
Sector	Healthcare
Industry	Medical - Devices
Country	US
Stage
Employee Count	186
Website	cytosorbents.com
LinkedIn	cytosorbents
Founders

Metric
Market Cap	53.76M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	36.35M
Revenue (LTM)
Revenue (NTM)
Gross Profit	22.39M
EBITDA	-28.53M
Operating Income	-30.55M
Net Income	-28.51M
EPS	-0.64
Diluted EPS	-0.64
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.64
Operating Profit Margin	-0.68
EBITDA Margin	-0.78
Net Profit Margin	-0.71
Return on Equity	-1.18
Return on Assets	-0.48
Return on Capital Employed	-0.57

COM:CYTOSORBENTS

CytoSorbents Corporation

Last Close

0.89

22/11 21:00

Market Cap

53.76M

Beta: -

Volume Today

76.86K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.90
P/B Ratio	2.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.34
EV Multiple	-1.09

Metric
Days Sales Outstanding	71.88
Days Payables Outstanding	88.26
Days Inventory Outstanding	119.65
Operating Cycle	198.74
Cash Conversion Cycle	114.28
Asset Turnover	0.73

Metric
Operating Cash Flow	-21.66M
Free Cash Flow	-22.59M
Cash Flow to Debt	-1.23
Operating Cash Flow/Sales	-0.59
Free Cash Flow Yield	-0.42

Metric
Cash & Equivalents	14.13M
Accounts Receivable	-245.62K
Inventory	3.68M
Goodwill
Debt to Capitalization	0.48
Debt to Assets	0.38
Current Ratio	1.61
Quick Ratio	1.71

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.12
R&D to Revenue	0.48
SG&A to Revenue	1.15